AdhexPharma

AdhexPharma is a specialized Contract Development and Manufacturing Organization (CDMO) headquartered in Chenôve, France. Established in 2008, the company focuses on the development and industrial-scale production of advanced drug-delivery systems, specifically transdermal patches and oral films. As a key player in the pharmaceutical sector, it supports partners throughout the entire product lifecycle, from initial R&D and formulation to commercial-scale cGMP manufacturing. The company is part of the Burgundy Ventures industrial holding and operates as a sister company to Adhex Technologies. With a strong emphasis on innovation, AdhexPharma utilizes its subsidiary, Labtec GmbH, as a center of excellence for research and development. The company has significantly expanded its global footprint and technical capabilities through strategic acquisitions, including the integration of AMW’s transdermal assets. Currently, AdhexPharma is investing in a major facility expansion in Chenôve to enhance its production capacity and sustainability, reinforcing its position as a leader in delivering complex dosage forms for the global pharmaceutical market.

AdhexPharma's mission is to provide specialized drug delivery expertise—specifically patches and oral films—to help partners bring innovative treatments to patients quickly and efficiently through a 'from idea to market' service model.

• Recognized by the Financial Times as a 'Long-Term Growth Champion' in the pharmaceutical sector.
• Construction of an 8,000 m² state-of-the-art facility in Chenôve to increase production capacity.
• Strategic acquisition of Labtec GmbH to bolster R&D capabilities.
• Maintains global compliance including cGMP and ISO 13485 certifications.
• Annual production capacity exceeding 100 million units.

Sources

• AdhexPharma Official Website
• Burgundy Ventures Portfolio